Celularity (CELU) Stock Price, News & Analysis

Company Overview

Celularity, Inc. (NASDAQ: CELU) is a biotechnology company developing and commercializing therapies and biomaterial products derived from human placental tissue. Its work focuses on regenerative medicine and cellular therapy, including allogeneic, or donor-derived, cell products intended for applications in oncology, immune-mediated diseases, and tissue repair.

The company’s research pipeline has included placenta-derived natural killer (NK) cell therapies, such as CYNK-001, an investigational product studied for certain blood cancers, and other cell-based programs designed to address cancer and inflammatory conditions. Celularity has also developed placental-derived biomaterials for wound care and surgical applications, including products based on amniotic membrane and placental connective tissue matrices.

Founded in 2016 by biotechnology and medical entrepreneur Robert J. Hariri, Celularity is headquartered in Florham Park, New Jersey. The company became a publicly traded business in 2021 through a merger with a special purpose acquisition company. Its products and development programs are intended for use in the United States and potentially other markets, subject to regulatory approvals and commercial availability.

Key Stats

• Today's Range: $0.80 to $0.87
• 50-Day Range: $0.75 to $2.10
• 52-Week Range: $0.56 to $2.55
• Volume: 180,748 shs
• Average Volume: 179,927 shs
• Market Capitalization: $25.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Celularity Stock Analysis - MarketRank™

Celularity scored higher than 10% of companies evaluated by MarketBeat, and ranked 855th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Celularity has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Celularity has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Celularity is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celularity is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.65% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 3.66, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Celularity has recently increased by 12.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celularity does not currently pay a dividend.

Dividend Growth

Celularity does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.02

News Sentiment

Celularity has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Celularity this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CELU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celularity insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.30% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.02% of the stock of Celularity is held by institutions.

Company Calendar

• Last Earnings: 10/20/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CELU
• CIK: 1752828
• Web: www.celularity.com
• Phone: 908-768-2170
• Fax: N/A
• Employees: 115
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$91.72 million
• Net Margins: -246.65%
• Pretax Margin: -245.66%
• Return on Equity: N/A
• Return on Assets: -48.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.10

Sales & Book Value

• Annual Sales: $18.67 million
• Price / Sales: 1.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.32) per share
• Price / Book: -0.61

Miscellaneous

• Outstanding Shares: 32,450,000
• Free Float: 26,836,000
• Market Cap: $25.96 million
• Optionable: Optionable
• Beta: 0.77